Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Ex Vivo Drug Response Profiling and Outcome Prediction in Lung Adenocarcinoma

NCT07636252 is registered in ClinicalTrials.gov with Sheba Medical Center as lead sponsor.

NCT NCT07636252
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07636252 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Ex Vivo Drug Response Profiling and Outcome Prediction in Lung Adenocarcinoma
Lead sponsor
Sheba Medical Center
Phase
Observational
Overall status
Recruiting
Start date
June 14, 2023
Completion date
January 1, 2030
Enrollment
400 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

lung adenocarcinoma, malignant pleural effusions (mpe)